Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2018, XLV/266: 081-088 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2018, XLV/266: 081-088

Title: Rational hypoglycemic therapy – nephro-diabetologic view 

Authors: Kosmalski M, Kurnatowska I. 

More details

08/266

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Rational hypoglycemic therapy – nephro-diabetologic view


Kosmalski M, Kurnatowska I.

Zakład Farmakologii Klinicznej, I Katedra Chorób Wewnętrznych Uniwersytetu Medycznego w Łodzi, Oddział Nefrologii, Uniwersytecki Szpital Kliniczny nr 1 im. N. Barlickiego w Łodzi.

Diabetes is a heterogenous group of diseases with chronic hyperglycemia, which is associated with the risk of many complications, including diabetic kidney disease. Micro- and macroangiopathy in hyperglycemic environment leads to organ failure, including end-stage renal disease, requiring dialysis or kidney transplantation. However, diabetes is not the only cause leading to kidney dysfunction in this patient population. A patient with diabetes should be monitored regularly for proteinuria and glomerular filtration rate and depending on advancement of kidney disease or suspicion other than diabetes cause of kidney damage, should also be covered by nephrological care. Appropriately selected hypoglycemic drugs and their doses, in combination with appropriate non-pharmacological treatment, in the patients with different stages of kidney disease, not only reduces the risk of drug-induced side effects but, above all, may slow the progression of kidney damage and reduce the risk of other complications in this group of patients. Recently, there have been many new groups of hypoglycemic agents that can be used in the treatment of patients with kidney disease. The aim of this study is to present the current possibilities of hypoglycemic therapy in patients with different stages of chronic kidney disease. In addition, the relationship between individual groups of hypoglycemic agents and the renal benefits and risk was analyzed.

Key words: diabetes mellitus, chronic kidney disease, hypoglycaemic drugs

Pol Med J, 2018; XLV (266); 81–88